OPR - Delayed Quote • USD KYMR Aug 2024 20.000 put (KYMR240816P00020000) Follow 0.9500 0.0000 (0.00%) At close: April 25 at 9:30 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for KYMR240816P00020000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KYMR Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release 20 Counties with the Highest Cancer Rates in the US Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher Kymera Therapeutics to Participate in Upcoming March Investor Conferences Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript Q4 2023 Kymera Therapeutics Inc Earnings Call